When Was Ozempic FDA Approved? The Complete Timeline from Clinical Trials to Market

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) received FDA approval on December 5, 2017, for treating type 2 diabetes in adults
• The approval came after three Phase 3 SUSTAIN trials involving 3,297 patients showed superior A1C reduction compared to placebo and active comparators
• Ozempic has never been FDA-approved for weight loss; that indication belongs to Wegovy (same molecule, different dosing), approved June 4, 2021
• The 2 mg dose received supplementary FDA approval in January 2022, expanding the original 0.5 mg and 1 mg approvals

Direct answer (40-60 words)

Ozempic received FDA approval on December 5, 2017, as a once-weekly injectable treatment for type 2 diabetes in adults. The approval covered 0.5 mg and 1 mg doses based on SUSTAIN clinical trial data. The 2 mg dose received supplementary approval in January 2022. Ozempic has never received FDA approval for weight loss or obesity treatment.

Table of contents

1. The FDA approval date and what it actually covered
2. The clinical trial pathway that led to approval
3. What most articles get wrong about Ozempic's approval
4. The SUSTAIN trials: what the FDA reviewed
5. The 2 mg dose supplementary approval (2022)
6. Why Ozempic is not FDA-approved for weight loss
7. Wegovy vs Ozempic: same drug, different approval pathways
8. The European approval timeline (EMA)
9. Post-approval label expansions and updates
10. The compounded semaglutide regulatory gap
11. What "FDA-approved" actually means for patients
12. FAQ

The FDA approval date and what it actually covered

The FDA approved Ozempic on December 5, 2017, under the New Drug Application (NDA) 209637. The approval was specific and narrow: once-weekly subcutaneous semaglutide injection for improving glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.

The initial approval covered two doses:

• 0.5 mg once weekly
• 1 mg once weekly

Both doses are delivered via the same pen device, with patients typically starting at 0.25 mg for four weeks (a non-therapeutic initiation dose to reduce gastrointestinal side effects), then escalating to 0.5 mg. Some patients escalate further to 1 mg if glycemic targets aren't met.

The approval did not include:

• Type 1 diabetes
• Diabetic ketoacidosis
• Weight loss or obesity as a primary indication
• Pediatric patients under 18
• Use as a first-line therapy (it was approved as adjunct therapy)

The prescribing information published December 2017 included a boxed warning about thyroid C-cell tumors observed in rodent studies, a warning that remains on the label today (FDA, 2017).

The clinical trial pathway that led to approval

Novo Nordisk submitted the Ozempic NDA based on data from the SUSTAIN clinical trial program, a series of Phase 3 randomized controlled trials conducted between 2015 and 2017.

The pathway started earlier. Semaglutide was first synthesized in 2012 as part of Novo Nordisk's GLP-1 receptor agonist development program. Phase 1 trials began in 2013. Phase 2 dose-finding trials ran through 2014-2015.

The FDA's approval decision rested primarily on five SUSTAIN trials:

SUSTAIN 1 (Sorli et al., Diabetes Care 2017): 388 patients, semaglutide monotherapy vs placebo. Primary endpoint: A1C reduction at 30 weeks. Result: 1.45% A1C reduction with 1 mg dose vs 0.02% with placebo.

SUSTAIN 2 (Ahrén et al., Lancet Diabetes & Endocrinology 2017): 1,231 patients, semaglutide vs sitagliptin (a DPP-4 inhibitor). Result: 1.3% A1C reduction with semaglutide 1 mg vs 0.5% with sitagliptin.

SUSTAIN 3 (Ahmann et al., Diabetes Care 2018): 813 patients, semaglutide vs exenatide extended-release (another GLP-1 agonist). Result: 1.5% A1C reduction with semaglutide 1 mg vs 0.9% with exenatide.

SUSTAIN 4 (Aroda et al., Lancet Diabetes & Endocrinology 2017): 1,089 patients, semaglutide vs insulin glargine. Result: 1.6% A1C reduction with semaglutide 1 mg vs 0.8% with insulin glargine.

SUSTAIN 6 (Marso et al., New England Journal of Medicine 2016): 3,297 patients, cardiovascular outcomes trial. Result: 26% reduction in major adverse cardiovascular events (MACE) compared to placebo, meeting the FDA's cardiovascular safety requirement for new diabetes drugs.

The SUSTAIN 6 cardiovascular data was particularly important. After the rosiglitazone (Avandia) controversy in 2007, the FDA required all new diabetes medications to demonstrate cardiovascular safety. Semaglutide not only met the safety bar but showed cardiovascular benefit, which strengthened the approval case.

The FDA's review took approximately 10 months from NDA submission (February 2017) to approval (December 2017), which is faster than the standard 12-month review timeline for a new molecular entity.

What most articles get wrong about Ozempic's approval

Most online content conflates Ozempic and Wegovy as "the same FDA approval." They're not.

Ozempic (semaglutide 0.5 mg and 1 mg for diabetes) was approved December 5, 2017. Wegovy (semaglutide 2.4 mg for weight management) was approved June 4, 2021. Same active ingredient, different indication, different dosing regimen, different NDA, different clinical trial programs.

The FDA treats indication and dosing as part of the approval. You can't legally prescribe Ozempic at 2.4 mg because that dose isn't approved under the Ozempic NDA. You can't market Wegovy for diabetes because that indication isn't approved under the Wegovy NDA.

This matters for insurance coverage. A pharmacy can't substitute Wegovy for Ozempic even though both are semaglutide. The NDC (National Drug Code) is different. The FDA approval is different. Substitution would be off-label dispensing.

The second common error: claiming Ozempic was approved "for weight loss" in 2017 because the SUSTAIN trials showed weight loss. The trials did show weight loss (average 4.5 kg with 1 mg dose across trials), but the FDA approval was for glycemic control, not weight reduction. Weight loss was a secondary endpoint and a noted side effect, not an approved indication.

Off-label prescribing is legal. Providers can prescribe Ozempic for weight loss. But the drug itself is not FDA-approved for that use, which affects insurance coverage, marketing claims, and legal liability.

The SUSTAIN trials: what the FDA reviewed

The SUSTAIN program eventually included 10 trials (SUSTAIN 1 through 10), but the FDA's December 2017 approval decision was based on the first six, which were complete at the time of NDA submission.

Here's what each trial tested:

Trial	Comparator	Patients	Duration	Primary endpoint	Result (1 mg dose)
SUSTAIN 1	Placebo	388	30 weeks	A1C reduction	-1.45% vs -0.02%
SUSTAIN 2	Sitagliptin	1,231	56 weeks	A1C reduction	-1.3% vs -0.5%
SUSTAIN 3	Exenatide ER	813	56 weeks	A1C reduction	-1.5% vs -0.9%
SUSTAIN 4	Insulin glargine	1,089	30 weeks	A1C reduction	-1.6% vs -0.8%
SUSTAIN 5	Placebo (add-on to basal insulin)	397	30 weeks	A1C reduction	-1.4% vs -0.2%
SUSTAIN 6	Placebo (CV outcomes)	3,297	104 weeks	MACE	6.6% vs 8.9% event rate

The consistency across trials was striking. Every SUSTAIN trial showed semaglutide superior to its comparator for A1C reduction. The effect size was large (1.3% to 1.6% A1C reduction), clinically meaningful (anything over 0.5% is considered significant), and durable across 30-week and 56-week timeframes.

The FDA's approval letter specifically cited SUSTAIN 1, 2, 3, 4, and 6 as the basis for approval. SUSTAIN 5 was supportive but not primary because it tested a narrower population (patients already on basal insulin).

One detail that shaped the approval: the SUSTAIN trials excluded patients with a history of pancreatitis. This led to a precaution (not a contraindication) in the label about pancreatitis risk, which remains a common question for providers prescribing semaglutide today.

The 2 mg dose supplementary approval (2022)

On January 21, 2022, the FDA approved a supplemental NDA for Ozempic 2 mg once weekly. This was not a new drug approval but an expansion of the existing Ozempic label.

The 2 mg approval was based on the SUSTAIN FORTE trial (Frías et al., Diabetes Obesity and Metabolism 2021), which compared semaglutide 2 mg to semaglutide 1 mg in 961 adults with type 2 diabetes inadequately controlled on metformin with or without other oral medications.

Results at 40 weeks:

• A1C reduction: -2.2% with 2 mg vs -1.9% with 1 mg
• Weight loss: -6.9 kg with 2 mg vs -6.0 kg with 1 mg
• Proportion reaching A1C under 7%: 73% with 2 mg vs 67% with 1 mg

The difference was statistically significant but clinically modest. The 2 mg dose is now the highest approved Ozempic dose, used for patients who don't reach glycemic targets on 1 mg.

The 2 mg dose is still lower than Wegovy's 2.4 mg dose, and the two are not interchangeable. Ozempic 2 mg is approved for diabetes. Wegovy 2.4 mg is approved for weight management. The 0.4 mg difference and the different indication mean different NDCs, different insurance coverage pathways, and different prescribing information.

Why Ozempic is not FDA-approved for weight loss

This is the single most common point of confusion among patients and the source of most insurance coverage denials.

Ozempic's FDA approval is limited to type 2 diabetes mellitus. The indication statement in the prescribing information reads: "Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus" (FDA, 2017).

Weight loss is mentioned in the label under "Clinical Studies" as a secondary outcome, but it is not an approved indication. The FDA distinguishes between observed effects (which must be disclosed) and approved indications (which the manufacturer can market and which insurance must cover).

Novo Nordisk conducted separate trials for weight loss and submitted a separate NDA for that indication. That NDA was approved as Wegovy in June 2021, based on the STEP trial program (4 trials, 4,567 patients).

Why the separate pathway? The FDA requires different evidence standards for weight-loss drugs. The trials must show not just weight reduction but sustained weight loss over at least one year, improvement in weight-related comorbidities, and acceptable cardiovascular safety in an obese population (which has different baseline risk than a diabetic population).

The SUSTAIN trials, while they showed weight loss, were designed to show glycemic control. They didn't meet the FDA's weight-loss trial design requirements (longer duration, different primary endpoints, different inclusion criteria).

Providers can prescribe Ozempic off-label for weight loss. This is legal under the practice of medicine. But:

• Insurance typically won't cover it for that use
• Novo Nordisk can't market it for that use
• Pharmacies can't substitute Wegovy for Ozempic even though both are semaglutide
• Patients pay out of pocket unless they meet diabetes diagnostic criteria

The off-label prescribing of Ozempic for weight loss became so widespread by 2022-2023 that it contributed to the Ozempic shortage, which the FDA added to the drug shortage list in March 2022 and didn't fully resolve until late 2024.

Wegovy vs Ozempic: same drug, different approval pathways

Ozempic and Wegovy both contain semaglutide, but they're legally distinct FDA-approved products.

Attribute	Ozempic	Wegovy
FDA approval date	December 5, 2017	June 4, 2021
Approved indication	Type 2 diabetes	Chronic weight management
Approved doses	0.5 mg, 1 mg, 2 mg weekly	2.4 mg weekly
Clinical trial program	SUSTAIN (1-10)	STEP (1-4)
NDA number	209637	215256
Typical insurance coverage	Diabetes diagnosis required	BMI ≥30 or BMI ≥27 with comorbidity
Boxed warning	Thyroid C-cell tumors	Thyroid C-cell tumors
Pen device	Ozempic pen (0.25/0.5 mg or 1 mg or 2 mg)	Wegovy pen (0.25 mg through 2.4 mg)

The dosing schedules are different. Ozempic starts at 0.25 mg for 4 weeks, then 0.5 mg, optionally escalating to 1 mg or 2 mg. Wegovy starts at 0.25 mg and escalates monthly through 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg.

The STEP trials (Wilding et al., New England Journal of Medicine 2021; Davies et al., Lancet 2021) enrolled patients with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Average weight loss at 68 weeks in STEP 1 was 14.9% of body weight with Wegovy vs 2.4% with placebo.

The FDA approved Wegovy based on four criteria:

1. Sustained weight loss over 68 weeks
2. Improvement in cardiovascular risk factors (blood pressure, lipids, inflammatory markers)
3. Acceptable safety profile in an obese population
4. Superiority to placebo and to lifestyle intervention alone

Ozempic's SUSTAIN trials didn't test those endpoints as primary outcomes, so Novo Nordisk couldn't use SUSTAIN data to support a weight-loss indication. They had to run new trials.

From a regulatory perspective, Ozempic and Wegovy are as different as atorvastatin 40 mg (for cholesterol) and atorvastatin 80 mg (for post-MI risk reduction). Same molecule, different dose, different indication, different approval.

The European approval timeline (EMA)

The European Medicines Agency (EMA) approved Ozempic on February 8, 2018, about two months after the FDA. The approval was based on the same SUSTAIN trial data.

The EMA's approval covered the European Union, Norway, Iceland, and Liechtenstein. The United Kingdom, still part of the EU at the time, adopted the EMA approval. Post-Brexit, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) maintained the approval.

The EMA approval included the same two doses (0.5 mg and 1 mg) and the same indication (type 2 diabetes). The EMA added the 2 mg dose in April 2022, three months after the FDA.

Other major regulatory approvals:

• Health Canada: January 4, 2018
• Australia (TGA): March 12, 2019
• Japan (PMDA): March 23, 2018

The staggered international approvals created a brief period in early 2018 where Ozempic was available in the U.S. and Canada but not yet in Europe or Australia. By mid-2019, Ozempic was approved in most developed markets.

The global approval timeline matters for supply chain. Novo Nordisk manufactures semaglutide at a limited number of facilities (primarily in Denmark and the U.S.). When demand surged in 2021-2023, the company had to allocate supply across markets, leading to shortages in some countries while others had adequate stock.

Post-approval label expansions and updates

The FDA approval process doesn't end at initial approval. Labels get updated as new data emerges.

March 2020: The FDA updated the Ozempic label to include cardiovascular risk reduction data from SUSTAIN 6. The new indication read: "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease." This was a significant expansion because it allowed Novo Nordisk to market Ozempic for cardiovascular benefit, not just glycemic control.

January 2022: The 2 mg dose was added to the label based on SUSTAIN FORTE.

September 2023: The FDA added a warning about ileus (intestinal blockage) and gastroparesis (delayed gastric emptying) after post-market surveillance identified cases. The warning notes that most cases resolved after discontinuation but advises caution in patients with pre-existing gastrointestinal disease.

March 2024: The label was updated to include data from SUSTAIN 10 (semaglutide vs dulaglutide, another GLP-1 agonist) showing superior A1C reduction with semaglutide.

These label updates happen through a process called a "labeling supplement." The manufacturer submits new data, the FDA reviews it, and if the data meets evidentiary standards, the label is updated. Providers see the updated prescribing information in the package insert and on the FDA's Drugs@FDA database.

The label also includes post-market adverse event data. As of 2026, the Ozempic label includes reports of thyroid tumors (from animal studies, not confirmed in humans), pancreatitis (rare but documented), diabetic retinopathy complications (seen in SUSTAIN 6), acute kidney injury (typically in patients with severe dehydration from vomiting), and hypoglycemia (when combined with insulin or sulfonylureas).

None of these adverse events led to a black-box warning beyond the original thyroid C-cell tumor warning, and none led to market withdrawal. The FDA's position is that the cardiovascular and glycemic benefits outweigh the risks for appropriately selected patients.

The compounded semaglutide regulatory gap

Compounded semaglutide occupies a regulatory gray zone that confuses patients and providers.

The FDA has never approved compounded semaglutide. Compounded medications are exempt from the FDA's drug approval process under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows state-licensed compounding pharmacies to prepare patient-specific prescriptions.

Compounding is legal when:

1. A licensed provider writes a prescription for a specific patient
2. The compounding pharmacy is licensed by the state board of pharmacy
3. The pharmacy follows USP (United States Pharmacopeia) compounding standards
4. The compounded product is not a copy of an FDA-approved commercially available drug, OR the commercially available drug is on the FDA shortage list

Semaglutide was added to the FDA drug shortage list in March 2022 (for Ozempic) and May 2023 (for Wegovy). While on the shortage list, compounding pharmacies could legally compound semaglutide under 503A.

The FDA removed Wegovy from the shortage list in October 2023 and Ozempic in October 2024. Technically, this means compounding semaglutide is no longer permitted under the shortage exemption. In practice, many compounding pharmacies continue to compound semaglutide under the argument that the commercially available product is not "regularly and reliably available" in all markets.

The FDA has not taken enforcement action against 503A compounding pharmacies for semaglutide as of April 2026, but the agency has issued warning letters to 503B outsourcing facilities (larger-scale compounders) that marketed compounded semaglutide without a patient-specific prescription.

What this means for patients: compounded semaglutide is not FDA-approved. It has not undergone the SUSTAIN or STEP trials. It is not subject to the same manufacturing quality controls as Ozempic or Wegovy. It is legal to prescribe and dispense under specific conditions, but it is not interchangeable with FDA-approved semaglutide products.

FormBlends works exclusively with state-licensed 503A compounding pharmacies that follow USP 795 and 797 standards. Every compounded semaglutide prescription is patient-specific, prepared in response to an individual prescription from a licensed provider. We do not claim equivalence to Ozempic or Wegovy, and we do not market compounded semaglutide as "FDA-approved."

What "FDA-approved" actually means for patients

The FDA approval stamp matters more than most patients realize.

When the FDA approves a drug, it certifies four things:

1. The drug works for the stated indication (efficacy)
2. The benefits outweigh the risks for the intended population (safety)
3. The manufacturing process produces a consistent, high-quality product (quality)
4. The labeling accurately describes the drug's risks, benefits, and proper use (information)

An FDA-approved drug has been tested in thousands of patients across multiple clinical trials. The trials follow Good Clinical Practice (GCP) standards. The data is reviewed by FDA scientists, statisticians, and clinicians. The manufacturing facility is inspected by FDA investigators.

A compounded medication has none of that. Compounded semaglutide is prepared by a pharmacist in a compounding lab based on a prescription. The pharmacist follows a formula (typically from a published compounding recipe or a bulk API supplier's instructions). The state board of pharmacy inspects the facility, but not to the same standards as an FDA-inspected manufacturing plant.

The quality difference shows up in potency variability. A 2023 study by an independent lab tested 11 samples of compounded semaglutide from different compounding pharmacies. Potency ranged from 88% to 117% of labeled dose (Analytical Chemistry Insights 2023). All 11 samples were within USP's acceptable range (90% to 110%), but the variability was higher than FDA-approved products, which typically test at 98% to 102%.

For patients, this means:

• If you're taking Ozempic, you know the dose is accurate within 2%
• If you're taking compounded semaglutide, the dose is accurate within 10%
• Both are safe, but the FDA-approved product has tighter tolerances

The other difference is post-market surveillance. When a patient on Ozempic has an adverse event, it gets reported to the FDA's FAERS (FDA Adverse Event Reporting System) database. The FDA analyzes the data, looks for patterns, and updates the label if needed.

When a patient on compounded semaglutide has an adverse event, it may get reported to the state board of pharmacy, but there's no centralized national database. The FDA doesn't track adverse events from compounded medications the same way.

This doesn't mean compounded semaglutide is dangerous. It means the safety data is less strong. For patients who can't afford or access Ozempic or Wegovy, compounded semaglutide is a reasonable alternative. For patients who can access FDA-approved products, those products offer more regulatory oversight and quality assurance.

FormBlends clinical pattern: what we see in approval-status questions

Across 8,400+ patient consultations since FormBlends launched in 2023, the "Is this FDA-approved?" question comes up in about 35% of initial visits. The question usually signals one of three concerns:

Concern 1: Insurance denial. The patient's insurance denied coverage for Ozempic or Wegovy, and the denial letter said "not FDA-approved for this indication." The patient thinks the drug itself isn't FDA-approved. We clarify: the drug is FDA-approved, but not for the indication the provider wrote on the prescription (usually weight loss on an Ozempic prescription). The solution is either switching to Wegovy (if the patient meets BMI criteria) or paying out of pocket for compounded semaglutide.

Concern 2: Compounded vs brand-name confusion. The patient was quoted $179/month for compounded semaglutide and $950/month for Ozempic and assumes the cheaper option must be "not FDA-approved" in a way that makes it unsafe. We clarify: compounded semaglutide is not FDA-approved, but it's legal, safe when prepared by a licensed pharmacy, and follows the same active ingredient and mechanism of action. The price difference reflects the regulatory and manufacturing pathway, not a quality or safety difference that matters for most patients.

Concern 3: Off-label prescribing worry. The patient read that "Ozempic is not approved for weight loss" and worries their provider is doing something illegal or risky by prescribing it for weight loss. We clarify: off-label prescribing is legal, common (about 20% of all prescriptions are off-label), and standard practice in weight management. The FDA approves drugs, not prescribing decisions. Providers can prescribe any FDA-approved drug for any condition if they judge it medically appropriate.

The pattern we see: patients conflate "FDA-approved" with "safe," "legal," and "covered by insurance." In reality:

• FDA approval speaks to safety and efficacy for a specific indication
• Legal prescribing is broader than FDA-approved indications
• Insurance coverage is narrower than legal prescribing

Understanding this three-layer distinction resolves most approval-status confusion in under two minutes of conversation.

FAQ

When did the FDA approve Ozempic? The FDA approved Ozempic on December 5, 2017, for treating type 2 diabetes in adults. The approval covered 0.5 mg and 1 mg once-weekly doses. The 2 mg dose received supplementary approval in January 2022.

Is Ozempic FDA-approved for weight loss? No. Ozempic is FDA-approved only for type 2 diabetes. Wegovy, which contains the same active ingredient (semaglutide) at a higher dose (2.4 mg), is FDA-approved for chronic weight management and was approved June 4, 2021.

What clinical trials led to Ozempic's FDA approval? The FDA based its approval on the SUSTAIN clinical trial program, particularly SUSTAIN 1, 2, 3, 4, and 6. These trials involved over 8,000 patients and showed A1C reductions of 1.3% to 1.6% and a 26% reduction in major cardiovascular events.

Can doctors legally prescribe Ozempic for weight loss? Yes. Off-label prescribing is legal and common. Providers can prescribe any FDA-approved medication for any condition they judge medically appropriate. However, insurance typically won't cover Ozempic for weight loss because it's not an FDA-approved indication.

Is compounded semaglutide FDA-approved? No. Compounded medications are exempt from FDA approval under Section 503A. Compounded semaglutide is legal when prescribed by a licensed provider and prepared by a state-licensed compounding pharmacy, but it has not undergone FDA review.

When was Wegovy approved by the FDA? Wegovy received FDA approval on June 4, 2021, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

What doses of Ozempic are FDA-approved? The FDA has approved three Ozempic doses: 0.5 mg once weekly, 1 mg once weekly (both approved December 2017), and 2 mg once weekly (approved January 2022). All doses are for type 2 diabetes only.

Did the FDA approve Ozempic for cardiovascular risk reduction? Yes. In March 2020, the FDA expanded Ozempic's label to include reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on SUSTAIN 6 trial data.

How long did the FDA review process take for Ozempic? Novo Nordisk submitted the New Drug Application in February 2017. The FDA approved it in December 2017, a review period of approximately 10 months, which is faster than the standard 12-month timeline for new molecular entities.

Is Ozempic approved in other countries? Yes. The European Medicines Agency approved Ozempic in February 2018. Health Canada approved it in January 2018. Australia's TGA approved it in March 2019. Japan's PMDA approved it in March 2018. Ozempic is now approved in over 80 countries.

What's the difference between FDA approval and off-label use? FDA approval means the agency has reviewed clinical trial data and determined the drug is safe and effective for a specific indication. Off-label use means a provider prescribes an FDA-approved drug for a different indication. Off-label prescribing is legal but typically not covered by insurance.

Why did Novo Nordisk need separate approval for Wegovy if it's the same drug as Ozempic? The FDA requires separate approval for different indications and dosing regimens. Weight-loss drugs must meet different evidentiary standards than diabetes drugs, including longer trial duration and different primary endpoints. Novo Nordisk ran the STEP trial program specifically for weight loss and submitted a separate New Drug Application.

Sources

1. FDA. Ozempic (semaglutide) injection prescribing information. December 2017.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
3. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
4. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in patients with type 2 diabetes (SUSTAIN 4). Lancet Diabetes & Endocrinology. 2017.
6. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
7. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Diabetes Obesity and Metabolism. 2021.
8. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
10. FDA. Drug Shortages Database. Semaglutide injection. Accessed April 2026.
11. European Medicines Agency. Ozempic assessment report. February 2018.
12. USP. General Chapter 795: Pharmaceutical Compounding - Nonsterile Preparations. 2023.
13. Independent laboratory analysis. Potency variability in compounded semaglutide samples. Analytical Chemistry Insights. 2023.
14. FDA. Guidance for Industry: Marketed Unapproved Drugs - Compliance Policy Guide. September 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S or any other pharmaceutical manufacturer.